Sponsors › University at Buffalo
University at Buffalo
Every GLP‑1 and incretin trial, approval and scheduled result we hold for University at Buffalo, drawn from ClinicalTrials.gov and Drugs@FDA.
University at Buffalo is an academic or hospital sponsor, not a drug company with 8 trials in the incretin class on file here, across 2 molecules. The programme is split between 1 early-stage trial and 7 in phase 3 or later.
- Molecules
- exenatide · liraglutide
- Trials on file
- 8
- Active trials
- 0
- Results scheduled
- 0
- Approved FDA submissions
- 0
Trials on file
All 8 incretin trials recorded for this sponsor, active first.